You are here

Tecentriq

Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths

Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths

Endpoints

clinical trials

Flag link:

Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week

Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week

Fierce Pharma

Flag link:

Roche's Tecentriq cocktail notches another lung cancer success

Roche's Tecentriq cocktail notches another lung cancer success

Yahoo/Reuters

clinical trials

Flag link:

Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?

Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?

Fierce Pharma

squamous non-small cell lung cancer

Flag link:

In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo

In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo

Fierce Pharma

PARP inhibitors

Flag link:

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

Endpoints

Flag link:

Roche's latest Tecentriq results shed little light on the lung cancer market race: analyst

Roche's latest Tecentriq results shed little light on the lung cancer market race: analyst

Fierce Pharma

Flag link:

Roche's Tecentriq combo cuts risk of lung cancer progression

Roche's Tecentriq combo cuts risk of lung cancer progression

BioPharma Dive

Flag link:

Roche Gains Ground on Rivals With Drug Combo’s Success in Lung Cancer

Roche Gains Ground on Rivals With Drug Combo’s Success in Lung Cancer

Xconomy

Flag link:

Roche's Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misfire

Roche's Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misfire

Fierce Pharma

Flag link:

Most new cancer meds haven't proved they can improve or extend lives: study

Most new cancer meds haven't proved they can improve or extend lives: study

Fierce Pharma

Flag link:

FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths

FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths

Endpoints

clinical trials

Flag link:

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

Fierce Pharma

clinical trials

Flag link:

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

BioPharma Dive

Flag link:

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster

Endpoints

Flag link:

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

Endpoints

clinical trials

Flag link:

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

Fierce Pharma

Flag link:

Roche's Tecentriq wins FDA OK as first-line treatment in bladder cancer

Roche's Tecentriq wins FDA OK as first-line treatment in bladder cancer

Fierce Pharma

Flag link:

4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't

4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't

Motley Fool

HER-2 postive breast cancer

multiple sclerosis

Flag link:

3 Big Pharma Companies With the Best Pipelines

3 Big Pharma Companies With the Best Pipelines

Motley Fool

Flag link:

Pages